132 related articles for article (PubMed ID: 9144773)
1. Solvation effects are responsible for the reduced inhibitor affinity of some HIV-1 PR mutants.
Sussman F; Villaverde MC; Davis A
Protein Sci; 1997 May; 6(5):1024-30. PubMed ID: 9144773
[TBL] [Abstract][Full Text] [Related]
2. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease.
Kar P; Lipowsky R; Knecht V
J Phys Chem B; 2013 May; 117(19):5793-805. PubMed ID: 23614718
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance.
Hong L; Zhang XC; Hartsuck JA; Tang J
Protein Sci; 2000 Oct; 9(10):1898-904. PubMed ID: 11106162
[TBL] [Abstract][Full Text] [Related]
4. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
Muzammil S; Ross P; Freire E
Biochemistry; 2003 Jan; 42(3):631-8. PubMed ID: 12534275
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease.
Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK
Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129
[TBL] [Abstract][Full Text] [Related]
6. Interpreting trends in the binding of cyclic ureas to HIV-1 protease.
Mardis KL; Luo R; Gilson MK
J Mol Biol; 2001 Jun; 309(2):507-17. PubMed ID: 11371168
[TBL] [Abstract][Full Text] [Related]
7. Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.
Meher BR; Wang Y
J Phys Chem B; 2012 Feb; 116(6):1884-900. PubMed ID: 22239286
[TBL] [Abstract][Full Text] [Related]
8. Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.
Meher BR; Wang Y
J Mol Graph Model; 2015 Mar; 56():60-73. PubMed ID: 25562662
[TBL] [Abstract][Full Text] [Related]
9. A structural and thermodynamic escape mechanism from a drug resistant mutation of the HIV-1 protease.
Vega S; Kang LW; Velazquez-Campoy A; Kiso Y; Amzel LM; Freire E
Proteins; 2004 May; 55(3):594-602. PubMed ID: 15103623
[TBL] [Abstract][Full Text] [Related]
10. Coarse-grained molecular dynamics of ligands binding into protein: The case of HIV-1 protease inhibitors.
Li D; Liu MS; Ji B; Hwang K; Huang Y
J Chem Phys; 2009 Jun; 130(21):215102. PubMed ID: 19508101
[TBL] [Abstract][Full Text] [Related]
11. Multidrug resistance to HIV-1 protease inhibition requires cooperative coupling between distal mutations.
Ohtaka H; Schön A; Freire E
Biochemistry; 2003 Nov; 42(46):13659-66. PubMed ID: 14622012
[TBL] [Abstract][Full Text] [Related]
12. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease.
Ohtaka H; Velázquez-Campoy A; Xie D; Freire E
Protein Sci; 2002 Aug; 11(8):1908-16. PubMed ID: 12142445
[TBL] [Abstract][Full Text] [Related]
13. Exploring the flap dynamics of the South African HIV subtype C protease in presence of FDA-approved inhibitors: MD study.
Maphumulo SI; Halder AK; Govender T; Maseko S; Maguire GEM; Honarparvar B; Kruger HG
Chem Biol Drug Des; 2018 Nov; 92(5):1899-1913. PubMed ID: 30003668
[TBL] [Abstract][Full Text] [Related]
14. I36T↑T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions.
Maseko SB; Padayachee E; Govender T; Sayed Y; Kruger G; Maguire GEM; Lin J
Biol Chem; 2017 Sep; 398(10):1109-1117. PubMed ID: 28525359
[TBL] [Abstract][Full Text] [Related]
15. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.
Wang YX; Freedberg DI; Yamazaki T; Wingfield PT; Stahl SJ; Kaufman JD; Kiso Y; Torchia DA
Biochemistry; 1996 Aug; 35(31):9945-50. PubMed ID: 8756455
[TBL] [Abstract][Full Text] [Related]
16. Crystal structures of HIV protease V82A and L90M mutants reveal changes in the indinavir-binding site.
Mahalingam B; Wang YF; Boross PI; Tozser J; Louis JM; Harrison RW; Weber IT
Eur J Biochem; 2004 Apr; 271(8):1516-24. PubMed ID: 15066177
[TBL] [Abstract][Full Text] [Related]
17. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
18. Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir.
Chen X; Weber IT; Harrison RW
J Mol Model; 2004 Dec; 10(5-6):373-81. PubMed ID: 15597206
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations.
Tzoupis H; Leonis G; Megariotis G; Supuran CT; Mavromoustakos T; Papadopoulos MG
J Med Chem; 2012 Jun; 55(12):5784-96. PubMed ID: 22621689
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics and free energy studies on the wild-type and mutated HIV-1 protease complexed with four approved drugs: mechanism of binding and drug resistance.
Alcaro S; Artese A; Ceccherini-Silberstein F; Ortuso F; Perno CF; Sing T; Svicher V
J Chem Inf Model; 2009 Jul; 49(7):1751-61. PubMed ID: 19537723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
